Blair Holbein

  • Citations Per Year
Learn More
Bavituximab is a chimeric monoclonal antibody with immune modulating and tumor-associated vascular disrupting properties demonstrated in models of non-small cell lung cancer (NSCLC). The molecular target of Bavituximab, phosphatidylserine (PS), is exposed on the outer leaflet of the membrane bi-layer of malignant vascular endothelial cells and tumor cells(More)
To determine whether early IM VE supplementation influences the incidence of IVH in infants ≤ 1500 gms, data were analyzed prospectively from 181 inborn infants enrolled on protocols of 2 consecutive yrs. In the first study, (1981C), 47 patients received 100 mg/kg/day of oral VE (3000 mOsM) daily with the first dose administered within 8 hrs of birth. In(More)
  • 1